Steve Bryson, PhD

Steve holds a PhD in Medical Biochemistry from the University of Toronto, Canada. He worked as a medical scientist in both industry and academia for two decades, with a focus on the design of new medicines for infectious diseases and immune-related disorders. In 2019, Steve joined Bionews as a science writer to help make the latest medical research more accessible for everyone.

Education

• PhD in Medical Biochemistry, University of Toronto, 1998
• BSc in Biochemistry, University of Toronto,1993

Published Works

• ClpP protease activation results from the reorganization of the electrostatic interaction networks at the entrance pores. Communications Biology (2019)
• The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. MAbs (2018)
• Biological evaluation and X-ray co-crystal structures of cyclohexylpyrrolidine ligands for trypanothione reductase, an enzyme from the redox metabolism of Trypanosoma. ChemMedChem (2018)
• Structures of preferred human IgV genes-based protective antibodies identify how conserved residues contact diverse antigens and assign source of specificity to CDR3 loop variation. Journal of Immunology (2016).
• Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity. Journal of Medicinal Chemistry (2016)
• Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase. ChemMedChem (2014)
• Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design. Journal of Biological Chemistry (2014)
• Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. Journal of Molecular Biology (2012)
• Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. Journal of Virology (2009)
• Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. Journal of Molecular Biology (2008)
• Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO Journal (2008)
• Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. Journal of Molecular Biology (2008)
• A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity. Molecular Immunology (2005)
• Highly conserved cysteines of mouse core 2 beta1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity. Journal of Biological Chemistry (2003)

Professional Accomplishments

• Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes. Patent CA2322838 (2000)

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.